FTSE 100 climbs after temporary easing of Trump tariff fears
FTSE 100 climbs after temporary easing of Trump tariff fears - An analyst said that a ‘positive mood’ was re-emerging on ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...
GSK Up Over 7%, On Track for Largest Percent Increase Since December 2022 — Data Talk
--On pace for largest percent increase since Dec. 6, 2022, when it rose 7.85% --Down 51.37% from its all-time closing high of $76.92 on Jan. 6, 1999 ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
STAT2h
This week in biotech earnings so far
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
American Association of Individual Investors2h
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...
FiercePharma2h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Top Stock Price Prediction: Strong Tailwinds On Nvidia, GSK, TSCM Stocks
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
Top Stock Price Prediction: Sentiment and Earnings Propel Nvidia, GSK, TSCM Stocks
Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...
Annual core operating profit increases for British pharma GSK
Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £23.55. The ...
GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...